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Abstract
The analysis of dynamic events in the tumor microenvironment during cancer progression is limited by the complexity of
current in vivo imaging models. This is coupled with an inability to rapidly modulate and visualize protein activity in real
time and to understand the consequence of these perturbations in vivo. We developed an intravital imaging approach that
allows the rapid induction and subsequent depletion of target protein levels within human cancer xenografts while
assessing the impact on cell behavior and morphology in real time. A conditionally stabilized fluorescent E-cadherin chimera
was expressed in metastatic breast cancer cells, and the impact of E-cadherin induction and depletion was visualized using
real-time confocal microscopy in a xenograft avian embryo model. We demonstrate the assessment of protein localization,
cell morphology and migration in cells undergoing epithelial-mesenchymal and mesenchymal-epithelial transitions in
breast tumors. This technique allows for precise control over protein activity in vivo while permitting the temporal analysis
of dynamic biophysical parameters.
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Introduction
Intravital imaging is a powerful tool to define the impact of
specific perturbations in target cells in real time, allowing one to
test concepts gathered in vitro while providing instructive
observations not readily captured by the histological evaluation
of tissue. In practice, intravital imaging approaches are limited by
our inability to: 1) rapidly toggle the expression level of target
proteins and; 2) visualize the impact on cellular biophysics in vivo
over physiologically relevant timeframes (12–48 hrs). While
imaging windows such as cranial, dorsal flap and mammary fat
pad windows permit intravital imaging of tumors, the require-
ments for anesthesia, surgery, hydration maintenance and control
of breathing motion artifacts during image acquisition must be
considered [1,2,3]. To circumvent these limitations, we have
developed a technique that combines protein-level chemical
modulation with a real-time imaging platform to visualize human
tumor xenografts in the shell-less chick embryo for extended
periods of time. Removing the requirement for invasive proce-
dures, anesthesia or feeding, this approach allows for continuous
intravital imaging for 48 hours or more without adverse effects on
the host or the cancer cell xenografts. Furthermore, the shell-less
configuration provides accessibility to the tumor and surrounding
vasculature, which permits the intravenous administration of a
chemical inducer during the imaging experiment.
Chemical induction systems based on the Tet-ON/OFF system
suffer from lengthy chemical induction lag [4], promoter leakiness
and variable doxycycline clearance times [5,6]. Doxycycline also
affects vascular permeability [7] and exhibits anti-angiogenic
activity [8,9] through inhibition of MMP-8, MMP-13 [10] and
MMP-9 transcription [11], making it less than ideal for the
investigation of the tumor microenvironment. In contrast, the
FKBP-destabilization domain (DD) and its chemical inducer,
Shield-1, is a chemical induction system that operates at the post-
translational level and overcomes many of the limitations
associated with transcription-level induction systems. A target
protein fused with the FKBP-DD tag is constitutively synthesized
but promptly degraded by the cell’s proteasome in the absence of
the hydrophilic small molecule, Shield-1 [12,13]. Upon the
addition of Shield-1 ligand, the FKBP-DD tag of the target
protein is stabilized through a direct binding event, preventing its
degradation and rendering the target protein active (Figure 1B)
[12,13]. The induction of protein activity is rapid, resulting in
accumulation of target protein within the cell within hours
(Figure 1B–C and [12]). Moreover, the depletion of Shield-1
results in an equally rapid transition to protein degradation, which
allows the user to ‘‘toggle’’ a target protein on and off during a
single continuous intravital imaging experiment.
We applied this imaging and induction technique to visualize
epithelial-mesenchymal transitions (EMT) in the MDA-MB-231-
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modulating intracellular levels of E-cadherin (E-cadh). E-cadherinis
a tumor suppressor protein [14,15] that is important for
maintaining cell-to-cell contacts between epithelial cells [16]. The
loss of E-cadherin expression is associated with an invasive
phenotype as observed in metastatic cancer cell lines [16,17]. Loss
of E-cadherin expression is a hallmark of epithelial-mesenchymal
transition (EMT), during which epithelial cells lose many of their
epithelial characteristics and acquire certain properties of mesen-
chymal cells, conferring increased motility and invasiveness.
Mounting evidence suggests that cancer cells exhibit a dynamic
plasticity between epithelial and mesenchymal states that allows
them to survive at distinct steps of metastasis [18,19,20,21]. While
the consequence of the manipulation of EMT-related factors has
been studied extensively, cycling of EMT has not been directly
visualized in vitro or in vivo in real-time. To achieve this, a chemically
inducible form of E-cadherin was introduced into MDA-MB-231-
luc-D3H2LN breast cancer cells (henceforth known as 231LN)
(Figure 1B), which express negligible levels of endogenous E-
cadherin similar to the parental MDA-MB-231 cell line (data not
shown) [22]. To determine the impact of this E-cadherin chimera
on EMT, we optimized conditions for the rapid induction and
depletion of E-cadherin with the objective of visualizing transitions
between mesenchymal and epithelial morphological states both in
vitro and in vivo. These transitions were captured in real time using
3D time-lapse videomicroscopy over periods of up to 48 hours.
This technique allows one to directly visualize the impact of
target protein modulation on human cells in vivo using intravital
Figure 1. A chemically tunable form of E-cadherin for use in intravital imaging. A) Expression vectors encoding tunable zsGreen (pzsGreen-
DD), fluorescent E-cadherin (pE-cadh-zsG) and tunable fluorescent E-cadherin (pE-cadh-zsG-DD). Components include CMV promoter (pCMV),
zsGreen fluorescent protein (zsGreen), the Shield-1 binding degradation domain (FKBP-DD), and E-cadherin. B) Schematic of MDA-MB-231-luc-
D3H2LN (231LN) cells used to express tunable proteins and the predicted behavior of cells in the presence or absence of Shield-1. 231LN tumor cells
were stably transfected with tdTomato and zsGreen alone or as a fusion with E-cadherin. C) Intravital imaging platform (right) with avian embryo
imaging chamber (left) to maintain proper temperature (37uC) and humidity (.90%) used to perform in vivo three dimensional time-lapse imaging of
micrometastases in the chorioallantoic membrane of the avian embryo.
doi:10.1371/journal.pone.0030177.g001
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objectives permits the dynamic visualization of target protein
subcellular localization, as well as the quantitation of key
biophysical information such as cell morphology and migration.
Importantly, this methodology is widely applicable to a wide
variety of cell types, target proteins, or higher throughput
approaches.
Results
Concentration-dependent kinetics of Shield-1 mediated
protein stabilization
To establish the kinetics of Shield-1-mediated target protein
modulation in the 231LN cell line, a vector encoding the green
fluorescent zsGreen protein fused in-frame with the DD domain
(protein: zsG-DD; vector: pzsG-DD – Figure 1A) was stably
introduced (Figure 1B). When these cells were treated with vehicle
(media + 1% EtOH), zsG-DD signal localized to perinuclear
compartments (Figure 2A) and no increase in total fluorescence
was observed over 24 hours (Figure 2C, Movie S1 – top panels).
Treatment with 0.5, 1.0, 2.0 and 5.0 mM Shield-1 resulted in an
equivalent rapid first-order increase in zsG-DD signal throughout
the cell interior (Figure 2B) over 24 hours (Figure 2C, Movie S1 -
1.0 mM treatment, bottom panels). This indicated that maximal
induction, presumably limited by the protein expression machin-
ery, was occurring at 0.5 mM Shield-1 and above. Treatment with
0.2 mM Shield-1 resulted in a bi-phasic induction kinetic as
evidenced by a lower slope in the induction curve after 4 hours of
treatment compared to the Shield-1 treatments .0.5 mM. This
indicated that Shield-1 levels were limiting at this concentration
after 4 hours of treatment with 0.2 mM and therefore this
concentration was utilized for the subsequent E-cadherin induc-
tion and depletion experiments. Moreover, the biphasic slopes in
the 0.2 mM Shield-1 treatment indicated that zsG-DD protein
exhibited minimal turnover and hence a long intracellular half-life,
thus validating its use as a reporter of Shield-1 bioavailability. In
the absence of Shield-1, zsG-DD protein (green channel) localized
with the 20S proteasome subunit (red channel) (Figure 2D) with a
Pearson’s coefficient of R=0.73, indicating substantial co-
localization within 231LN cells. In addition to establishing the
concentration-dependent kinetics of Shield-1 mediated protein
stabilization, these experiments suggested that 231LN cells
expressing tunable zsG-DD protein would be suitable pharmaco-
kinetic reporters of Shield-1 bioavailability.
Toggling the accumulation and degradation of
E-cadherin to mediate EMT
E-cadherin plays a pivotal role in the establishment and
stabilization of the cell-cell junctions that are characteristic of
epithelial cells, and cultured 231LN cells exhibit a spindle-shaped,
mesenchymal cell morphology in vitro (Figure 3A - top panels) but
can assume an epithelial, cobble-stone morphology when E-
cadherin is re-expressed [22,23]. We expected that inducing the
accumulation of E-cadherin would result in a morphological
transition from a mesenchymal morphology to an epithelial one.
To confirm this in our model, E-cadherin was stably expressed in
231LN cells. In contrast to the parental cells (Figure 3A, top
panels), stable re-expression of E-cadherin-zsG (E-cadh-zsG)
induced the formation of zsG-labeled junctions (arrows) and an
epithelial, cobblestone morphology (Figure 3A, second row of
panels from the top). Next, the effect of Shield-1 mediated
induction of E-cadherin expression was assessed in real time using
time-lapse fluorescence microscopy. In the absence of Shield-1,
231LN cells expressing a tunable fluorescent E-cadherin-DD (E-
cadh-zsG-DD) continued to exhibit a mesenchymal morphology
(Figure 3A, third row of panels from the top), while Shield-1
treated cells rapidly formed cell-cell junctions (arrows) and
transitioned to an epithelial morphology (Figure 3, last row of
panels). A monoclonal antibody for human E-cadherin confirmed
the membrane localization of stabilized E-cadh-zsG-DD in
immunostained 231LN cells treated with Shield-1 (Figure 4A),
and overall levels of E-cadherin in these cells accumulated over 24
hours as demonstrated by Western blot (Figure 4B). Taken
together, these observations validate that the tunable chimera E-
cadh-zsG-DD is efficiently induced by Shield-1 and behaves
equivalently to re-expressed native E-cadherin.
Induction of E-cadh-zsG-DD expression in 231LN cells resulted
in a shape change from a spindle mesenchymal morphology to an
polygonal epithelial morphology. To quantitate this change in
shape, circularity measurements of individual cells from each
group (Figure 3B) was used. Circularity measures the ‘‘roundness’’
of the two-dimensional shape of each cell, hence a perfect circle
will exhibit a circularity value of 1.0, an epithelial cell will exhibit a
circularity value approximating 1.0, while a spindle-shaped cell
will exhibit a circularity value approximating 0.0. For example,
231LN cells in Figure 3B (left panel) exhibit a circularity value of
0.276 because of their elongated spindle shape (Figure 3B, left
panel) [24,25,26,27], whereas over-expression of E-cad-zsG in
these same cells will induce a shape change to a polygonal
epithelial morphology with a circularity value of 0.839 (Figure 3B,
right panel). Overall, Shield-1 induction of E-cadh-zsG-DD in
231LN cells induced a shape change to a more rounded
morphology (Figure 3C), as evidenced by a significantly higher
circularity index value compared to 231LN cells (far left) and
vehicle treated cells (second from right) and similar to circularity
values exhibited by the 231LN cells expressing E-cadh-zsG
(second from left, * denotes p,0.01, one-way ANOVA, N=70
each group).
Alongside the observed changes in cell shape due to E-cadh-
zsG-DD induction, protein levels of EMT markers such as
vimentin were also changed with Shield-1 treatment. In the
presence of vehicle, cells expressed high levels of vimentin and
negligible levels of E-cadh-zsG-DD protein consistent with the
mesenchymal phenotype of the 231LN cells. However, treatment
with 1.0 mM Shield-1 for 12 hours resulted in an increase in E-
cadh-zsG-DD protein and a decrease in vimentin protein levels.
The expression levels of these EMT markers according to
immunoblot analysis underscores the observed shape change from
a mesenchymal to epithelial phenotype upon Shield-1 induction.
Given the rapid kinetics of target protein accumulation and the
establishment of a Shield-1-limited dose, we surmised that E-
cadherin accumulation and degradation in the 231LN cell line
could be "toggled" by the introduction and withdrawal of Shield-1.
To assess this, 231LN cells expressing tunable E-cadherin (E-cadh-
zsG-DD) were treated with 0.2 mM Shield-1 and visualized over 24
hours using time-lapse fluorescence microscopy. E-cadherin-
positive junctions were measured by tracing the outline of each
cell, tracing the zsGreen positive junctions where the cells intersect,
and then determining the cumulative length using ImageJ.
Compared to vehicle treatment (Figure 5A –Movie S2, top panels),
0.2 mM Shield-1 treatment resulted in the formation of E-cadherin-
containing junctions between neighboring cells within 4 hours
(Movie S2, bottom panels). These junctions remained intact and
then declined over the next 8 hours (Figure 5B – Movie S2, bottom
panels), coinciding with the Shield-1-limited kinetics observed in
cells expressing tunable zsGreen (Figure 2C and Figure 5C left
panel). While the 0.5 and 1.0 mM Shield-1 treatments result in a
rapid induction effect, Shield-1 depletion was not observed under
In Vivo Imaging of Inducible Proteins
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confirm that these observations were indeed due to the depletion of
bioavailable Shield-1, conditioned media from tunable zsGreen
cells treated with 0.2 mM and 5.0 mM Shield-1 ligand at 0, 6, and
12 hrs post-treatment were used to treat 231LN cells expressing
tunable E-cadherin (E-cadh-zsG-DD). Conditioned media from
0.2 mM Shield-1-treated cells collected at 6 and 12 hrs post-
induction was not capable of inducing E-cadh-zsG-DD accumula-
tion in cells expressing E-cadh-zsG-DD (Figure 5D), whereas media
from earlier timepoints or media from cells treated with 5.0 mM
Shield-1 at all timepoints retained the ability to induce E-cadh-zsG-
DD in cells expressing E-cad-zsG-DD. These data demonstrate that
target proteins such as zsG-DD and E-cadh-zsG-DD can be rapidly
induced and then degraded in 231LN cells within 24 hours with
predictable kinetics when a 0.2 mM Shield-1 concentration is
utilized. Furthermore, when the accumulation of E-cadherin is
toggled in this manner in 231LN cells, an inducible but transient
epithelial morphology can be observed.
Figure 2. Rapid induction of the fluorescent protein zsGreen in MDA-MB-231LN (231LN) cells in vitro. 231LN cells containing both
tdTomato and zsGreen-DD were grown on glass coverslips. Panels represent fluorescence time-lapse imaging of 231LN cells treated with vehicle (A)
and 1.0 mM of Shield (B). C) Quantification of zsGreen signal within the cells in the presence and absence of Shield-1 over time (*denotes p,0.01
compared to Vehicle treatment kinetic, N.10 cells per field of view, 10 fields of view analyzed per group). Treatment with 0.5, 1.0 and 2.0 mM Shield-1
revealed similar first order kinetics, while treatment with 0.2 mM Shield-1 revealed a similarly steep but brief increase (induction) in signal
accumulation followed by a less steep kinetic at 4 hours post-treatment (depletion kinetic). D) Fluorescence immunohistochemistry demonstrates co-
localization of proteasome (a1-20S antibody in red) with zsGreen-DD signal in 231LN cells in the absence of Shield-1. All scale bars are 25 mm.
doi:10.1371/journal.pone.0030177.g002
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bioavailability
To assess the pharmacokinetics of Shield-1 in the shell-less avian
embryo xenograft model, 231LN cells expressing tunable zsGreen
(zsG-DD) were injected intravenously and allowed to extravasate
and form micrometastatic colonies as we have previously described
[28]. The response of the tumor cells to the systemic administra-
tion of a range of Shield-1 concentrations was assessed in vivo using
intravital confocal microscopy whereby three dimensional time-
lapse movies were acquired at high magnification for 12-18 hours
(Figure 6, Movie S3). Micrometastatic colonies of 231LN cells,
identified by virtue of their cytoplasmic tdTomato fluorescence,
were assessed for changes in zsGreen signal subsequent to
intravenous Shield-1 administration (Figure 6D). At final Shield-
1 concentrations ranging from an estimated 0.2–1.0 mM , an initial
and rapid accumulation of zsG-DD protein was observed in the
cytoplasm of 231LN cells (Figure 6A–C) while exhibiting no
observable toxic effects on avian embryo viability. The time to
attain maximal fluorescence and the degree of maximal fluores-
cence was Shield-1 concentration-dependent (Figure 6D), and was
Figure 3. Characterization of tunable E-cadherin-zsG-DD protein expression in 231LN cells in vitro. A) Representative images of 231LN
cells expressing fluorescent E-cadherin chimeras. Cell nucleus as stained by Hoechst (blue), E-cadherin-zsGreen (green), and tdTomato to highlight
the cytoplasm (red) reveal the changes in cell morphology when E-cadherin is over-expressed (row 2) or induced with Shield-1 for 12 hours (row 4)
compared to control (row 1) or un-induced cells (row 3). Arrows (yellow) highlight junctions formed by Shield-1-stabilized E-cadh-zG-DD. Scale bars
are 20 mm. Insets show magnified view (250%) of cellular junctions. B) Examples of circularity measurements of representative 231LN cells (left) and
231LN cells expressing E-cadh-zsG-DD treated with 1.0 mM Shield-1 (right). C) Circularity measurements to assess a mesenchymal vs. epithelial
morphology in cells described above. N=70 per group, * denotes p,0.01 between groups, 2-way ANOVA.
doi:10.1371/journal.pone.0030177.g003
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estimated 0.5 mM final Shield-1 concentration generated a
consistent and reproducible induction of zsG-DD that peaked at
6 hours, followed by a degradation phase that returned to half-
maximal fluorescence by 10 hours. These experiments established
the utility of 231LN cells expressing the tunable zsGreen protein as
a useful in vivo reporter for the real-time bioavailability of Shield-1.
Furthermore, they confirm the feasibility of performing both
induction and degradation phase analyses of target proteins during
a single continuous intravital imaging experiment.
Intravital visualization of reversible mesenchymal to
epithelial transitions in cancer cells in vivo
Proof of principle experiments were conducted to assess the
impact of sustained and transient expression of E-cadherin in
micrometastatic 231LN tumor cell colonies. For the sustained
induction experiments, a 1.0 mM Shield-1 final concentration in
vivo was selected as this generated a persistent induction stimulus.
Micrometastatic colonies were visualized using intravital confocal
imaging over a period of 40 hours. When a 1.0 mM Shield-1
Figure 4. Induction of E-cadherin-zsG-DD protein in 231LN cells by Shield-1 ligand and expression of vimentin. A) 231LN cells
expressing E-cadh-zsG-DD (green) treated with 1.0 mM Shield-1 for 24 hours and immunostained with anti-E-cadherin mAb (red) and Hoechst nuclear
stain (blue). Scale bars are 25 mm. B) Western immunoblot analysis of E-cadherin expression in 231LN cells expressing E-cadh-zsG-DD and treated with
1.0 mM Shield-1 using the same mAb as in A). Graph (right) represents analyses performed on three independent induction experiments. Cell lysates
of 231LN cells expressing E-cadherin-zsG are shown in the first lane. Lysates of cells expressing E-cadherin-zsG-DD were collected at 0, 4, 8, 12, 16, and
24 hrs after Shield-1 treatment (1.0 mM final), revealing accumulation of Shield-1 stabilized E-cadherin-zsG-DD within cells (,135 kDa). Far right lane
is a positive control of 21PT cells [32] which endogenously express high levels of E-cadherin (,110 kDa). C) Western immunoblot analysis of markers
for epithelial-mesenchymal transition (EMT). Blot (left panels) reveals a decrease in vimentin protein levels when E-cadh-zsG-DD is induced by 1.0 mM
Shield-1 treatment. Graph (right) represents analyses performed on three independent induction experiments.
doi:10.1371/journal.pone.0030177.g004
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PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30177Figure 5. Time-lapse imaging of E-cadherin induction and kinetics of cell-cell junction formation in vitro. Fluorescence in vitro time-
lapse imaging of 231LN cells containing inducible E-cadherin treated with vehicle (A) or 0.2 mM Shield-1 which will produce an induction and
depletion effect over 24 hours (B). Data Scale bar is 25 mm. C) Measure of ‘‘actively engaged" E-cadherin in 231LN cells in the presence of varying
levels of Shield-1 (0.2, 0.5, and 1.0 mM Shield-1), expressed as the cumulative length of all zsG-positive adherens junctions over time (mm/hrs) in
representative time-lapse experiments. The black kinetic represents the total cumulative length of E-cadherin-based junctions within a field of view at
that timepoint while the red kinetic represents the accumulation of zsGreen-DD exposed to similar Shield-1 treatment. The ‘‘induction’’ and
‘‘depletion’’ phases of chemical induction are annotated in each graph. D) Conditioned media collected from cells expressing pzsGreen-DD which
were treated with 0.2 mM Shield for 0, 6 and 12 hours were used to induce E-cadherin-zsGreen-DD expression in 231LN cells expressing E-cad-zsG-DD.
There is induction with the 0 and 6 hours conditioned media, but minimal effect with the 12 hour conditioned media. Conversely, conditioned media
from cells treated with 5.0 mM Shield-1 induced E-cadherin-zsG-DD expression regardless of the time of conditioned media collection. Graph
(Figure 5D, right) represents data from three independent western immunoblot experiments.
doi:10.1371/journal.pone.0030177.g005
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30177Figure 6. Intravital time-lapse imaging of fluorescent protein induction in 231LN cells in vivo. 231LN cells expressing tdTomato (red) and
inducible zsGreen-DD (green) were injected intravenously in the avian embryo and allowed to extravasate and proliferate into micrometastases.
Representative time-lapse images (maximum intensity projections) are shown after intravenous administration of Vehicle (A), 0.2 mM Shield-1 (B), and
0.5 mM Shield-1 (C). D) Quantification of in vivo zsGreen fluorescence in tdTomato-positive cells over time. Data for Vehicle (black kinetic), 0.2 mM
Shield-1 (red kinetic), 0.5 mM Shield-1 (green kinetic), and 1.0 mM Shield-1 (blue kinetic) are represented as averages of at least three movies analyzed
in each group. Error bars are SE and scale bar represents 25 mm.
doi:10.1371/journal.pone.0030177.g006
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transitioned from an invasive mesenchymal morphology to a
tightly packed "globular" epithelial morphology (Figure 7A, Movie
S4). Increasingly stable cell-cell junctions were clearly observed
between tumor cells, highlighted by the Shield-1 stabilized
fluorescent E-cadh-zsG-DD protein. The intravenous administra-
tion of 0.2 mM Shield-1 did not result in any E-cadherin induction
in vivo (Figure 7B, Movie S5) and therefore Shield-1 final
concentrations of 0.5 mM and above were used for visualizing
transitions between the mesenchymal and epithelial cell states.
These experiments clearly illustrate that sustained E-cadherin
expression is sufficient to alter the morphology and behavior of
231LN cells in vivo. To test whether the observed changes would
persist after a subsequent destabilization of E-cadh-zsG-DD, chick
embryos bearing 231LN micrometastases were treated with
0.5 mM Shield-1. Again, induction of E-cadherin resulted in a
rapid morphological transition to an epithelial phenotype during
the initial 6 hours, concurrent with an accumulation of fluorescent
E-cadherin chimera at the tumor cell junctions (Figure 7C, Movie
S6). The morphological transition is particularly dramatic when
compared to a cell in the same field that does not express the E-
cadherin chimera, exhibiting a highly invasive morphology. This
cell does not exhibit E-cadh-zsG-DD signal over the entire time
course as revealed in the single Z-plane image set presented in
Figure 7C and D. This dynamic morphological effect caused by
Shield-1 induction is further conveyed upon comparison to other
tdTomato-positive cells within the field of view, which do not
assume an epithelial morphology throughout the entire time
course. After 15 hours, E-cadh-zsG-DD dissociates from the cell
junctions and the cells revert back to their spindle-shaped,
mesenchymal morphology (Figure 7D, Movie S7). The localiza-
tion of E-cadh-zsG-DD at t=28 hours is comparable to that at
t=0 hours, confirming that the degradation of the E-cadherin
chimera has resumed. Of note, is that the initial mesenchymal
morphology at t=0 is not identical to the final mesenchymal
morphology at t=28 due to cell proliferation, migration and E-
cadh-zsG-DD induction. These experiments demonstrate that
consistent and sustained levels of E-cadh-zsG-DD are required to
maintain an epithelial morphology in 231LN cells and that the
destabilization of E-cadherin results in a rapid reversion to a more
mesenchymal and invasive morphology.
Discussion
This technique is particularly useful for the visualization of
dynamic transitions in cellular morphology in response to the
rapid induction and/or degradation of a transgenic protein, such
as those that mediate EMT. The coupling of a responsive chemical
induction system with a long term in vivo imaging platform allows
for a precise linkage between the level of target protein with the
collection of both qualitative morphological and quantitative
biophysical information. Given the technical challenges of
continuous real-time intravital imaging of subcellular structures,
the timing of induction and knowledge of any prolonged effect is
critical in the interpretation of cell biophysics, such as during
chemically-induced perturbations of cell function. Cell biophysical
parameters such as morphology, cell protrusion formation and
migration can be simultaneously assessed during Shield-1
mediated induction of a target protein, while avoiding the
induction lag suffered by Tet-ON/OFF systems.
Rapid induction and depletion in a sequential manner is
possible because regulation of activity occurs at the post-
translational level; wherein the presence of chemical inducer
becomes the limiting factor while the magnitude of supply will
dictate the length of an induction effect. An important consider-
ation with this technique is the compatibility of the protein of
interest to the FKBP-DD (DD) protein tag. Because the target
protein is tagged with both the DD domain (107 aa) and a
fluorescent protein, the utility of this approach is limited to those
proteins that can tolerate tags of this size while retaining function.
The fluorescent tag can be omitted, but this will prevent intravital
visualization of protein localization within the cell of interest and
prevent visual confirmation of protein induction. The latter
concern can be alleviated by introducing a transgene encoding a
DD-tagged fluorescent protein in addition to the DD-tagged target
protein. It must also be considered that in the absence of Shield-1,
the target protein is translated in its entirety and may therefore be
functional for a brief period prior to its degradation in the
proteasome. This may also preclude studies involving proteins that
affect proteasome function.
Visualizing the intracellular and biophysical impact of rapidly
induced target protein offers a unique opportunity to evaluate
genes of interest that have putative simultaneous effects on cell
migration, morphology, and proliferation. For example, induction
of E-cadherin activity within cancer xenografts resulted in the
formation of junctions between mesenchymal cancer cells, causing
increased cell-cell contacts within the micrometastatic colony.
However, induction and subsequent depletion of a target protein
may not necessarily result in a complete reversion back to the
original morphology, as this will depend on the length of the time
course and the nature of the effector protein. While the relevance
of EMT in cancer metastasis is the focus of ongoing debate, our
results demonstrate that transitions between the epithelial and
mesenchymal state in vitro and in vivo can be in fact, rapid and
inducible. While scores of presumed inducers of EMT have been
described, the full impact of very few have been characterized as
rigorously as E-cadherin. This approach can facilitate a straight-
forward assessment of those factors that putatively induce or revert
EMT in vivo and to determine if these presumed factors are
relevant to specific steps of cancer metastasis.
In addition to the application described herein, there are a
number of complex and dynamic events, such as chemotaxis or
apoptosis, that can be studied using this technique that are difficult
or impractical to evaluate in other in vivo imaging models. For
example, the ‘‘pulsed’’ induction of a putative chemotactic factor
secreted by cancer xenografts could be used to observe the
magnitude and rate of immune cell recruitment at sites of
chemokine release. Similar approaches can be applied during
assessment of putative pro-apoptotic factors in chemotherapy-
resistant cancer cells. The analysis of apoptosis by end-point assays
is limited as it relies on the absence of cancer cells at pre-
determined timepoints. One can utilize this technique to
quantitatively assess cancer cell death over time when target
protein levels are toggled, while simultaneously providing
information on the compartmentalization of the target protein
prior to cell death. Overall, the optimization of several key
components, including the shell-less embryo model, the develop-
ment of the intravital imaging platform, and the relationship
between Shield-1 dosing in vitro and in vivo, make this method
highly accessible and broadly applicable to a wide range of
experiments that require visualization of dynamic events in vivo.
Materials and Methods
Reagents and constructs and cells
The full length human E-cadherin cDNA clone was a kind gift
of Dr. Margaret Wheelock (U of Nebraska Medical Centre,
Omaha, NE) and the FKBP-DD L106P cDNA was provided by
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PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e30177Figure 7. Induction of E-cadherin causes morphological changes in 231LN micrometastases. 231LN cells expressing tdTomato (red) and
tunable E-cadherin-zsGreen-DD (green) were injected intravenously in the avian embryo and allowed to extravasate and proliferate into
micrometastases. Representative maximum intensity projections are shown. A) In vivo treatment with 1.0 mM Shield-1 demonstrates transition from a
mesenchymal morphology to an epithelial morphology and continued maintenance of the epithelial morphology over an extended period of time
(.40 hrs). Formation of E-cadherin junctions is apparent at t=0.5 hrs, increasing through 24 hrs. B) Representative micrometastatic colony
expressing tunable E-cadherin-zsG-DD and treated with 0.2 mM Shield-1. No induction effect is observed with 0.2 mM Shield-1 in vivo. C) Single Z-
plane slices of a representative micrometastastic colony expressing tunable E-cadherin-zsG-DD and treated with 0.5 mM Shield-1. These panels
represent the stabilization effect induced by 0.5 mM Shield-1 over the 12 hour time course; E-cadh-zsG-DD is stabilized and junctions appear between
231LN cells. E-cadh-zsG-DD junctions between cells of the micrometastatic colony are highlighted by arrows. D) Panels represent the depletion effect
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TdTomato vector was a generous gift of Dr. Roger Tsien (UC San
Diego) and pzsGreenC-1 vector was purchased from Clontech
Inc., (Mountain View, CA). The small molecule, Shield-1, was
purchased from Cheminpharma Inc, (New Haven, CT) and
reconstituted in 100% EtOH. The monoclonal antibody for E-
cadherin was from BD Pharmingen (Burlington, ON), the
monoclonal antibody for vimentin was from Dako (clone 3B4,
Burlington, ON), the monoclonal antibody to detect 20S
proteasome was Subunit b1, clone MCP421 from Biomol
(Burlington, ON), and the Goat anti-mouse Alexa647 secondary
antibody and Hoechst 33345 were from Invitrogen (San Diego,
CA). The lymphotrophic MDA-MB-231-luc-D3H2LN (231LN)
cell line was from Caliper Life Sciences (Hopkinton, MA). MEM
media supplemented with 10% FBS, sodium pyruvate and non-
essential amino acids (NEAA) was used for cell culture (Invitro-
gen). To facilitate detection of the breast cancer cells in vitro and in
vivo, a stable red fluorescent protein-expressing variant was made
by transfection of tdTomato into 231LN cells. Briefly, 2 mgo f
tdTomato cDNA in pcDNA-3.1 hygro was nucleofected into cells
using the Nucleofector device as specified by manufacturer (Lonza,
Burlington ON, Canada). Nucleofected cells were plated in 6 well
dishes for 24 hours prior to adding drug selection pressure for 14
days. Complete media containing hygromycin (700 mg/ml) was
replenished every 3 days. High tdTomato expressing clones were
isolated by fluorescence activated cell sorting using a BD
FACSVantage DiVa cell sorter equipped with 488 nm/633 nm/
UV lasers. To generate the pzsG-DD construct, the destabilization
domain (DD) cDNA was inserted into the 39 end of the zsGreen
sequence in the pzsGreen-C1 with a 4 alanine residue linker. The
human E-cadherin cDNA was inserted into the 59 end of the
zsGreen sequence in the pzsG-DD construct (pEcadh-zsG-DD) or
into the 59 end of the zsGreen sequence in the pzsGreen-C1
construct (pEcadh-zsG). The 231LN cell was stably transfected
with a construct that constitutively expressed the red fluorescent
protein tdTomato. These 231LN-tdTomato cells were then stably
transfected with either pzsGreen, pzsG-DD, pEcadhzsG, or
pEcadh-zsG-DD constructs.
Fluorescence microscopy
For static confocal fluorescence imaging, an Olympus Fluoview
confocal microscope was used and ImageJ was used for all image
processing. For time-lapse live cell imaging, a Zeiss Axiovert
upright fluorescence microscope with both 10X and LD 20X
objectives and a Weatherstation to maintain temperature and
humidity were used. For intravital spinning disk confocal
microscopy, a specialized instrument (Quorum Technologies,
Guelph, ON, Canada) comprised of an upright Zeiss AxioEx-
aminer Z1, Ludl filter wheels and large format motorized stage, a
Yokogawa spinning disk head, a Hamamatsu 9100-12 ImageEM
CCD camera, controlled by Volocity (Improvision, UK) was used
to acquire all images and all image processing, image analysis and
movie development was done with Volocity and ImageJ [29].
Imaging of cells in culture
For all in vitro experiments, stable cell lines were plated on
24 mm No. 1 circular coverslips at 70% confluency prior to
Shield-1 or vehicle treatment unless stated otherwise. To fix cells,
1% paraformaldehyde in PBS pH 7.2 was used and 0.05%
Saponin with 1% albumin in PBS pH 7.2 was used to
permeabilize cells for immunofluorescence staining. Prolong Gold
Anti-fade mounting media (Invitrogen, CA) was used to mount
cells onto glass slides. For real-time live cell imaging, cells plated
onto circular coverslips were transferred and mounted into a
specialized imaging chamber for use with an upright microscope.
This specialized imaging chamber is a closed system and was
supplemented with 20 mM HEPES buffer (pH 7.2). The upright
microscope is fitted with a temperature regulated enclosure to
maintain a temperature of 37uC. All live cell imaging experiments
were conducted for a minimum of 16 hours.
In vivo videomicroscopy of avian embryo chorioallantoic
membrane (CAM)
231LN cells (2610
6 cells/CAM) containing the zsGreen-DD or
Ecadherin-zsG-DD construct were injected intravenously into a
CAM venule of a day 9 old embryo as previously described in
[28]. After five days of growth, Shield-1 or ethanol vehicle (in
4%EtOH, 100 mL/CAM) was injected intravenously [28,30] to a
final concentration of 1 or 2 mM Shield-1 as indicated. The
average volume of a day 15 avian embryo is 8 mL[31]. Assuming
Shield-1 will be uniformly distributed if injected intravenously, to
establish a 1 mM final concentration of Shield-1, 100 mL of diluted
Shield-1 (4 mL of 2 mM Shield-1 stock added to 96 mL PBS) was
injected intravenously. To establish a 2 mM concentration of
Shield-1, 8 mM of 2 mM Shield-1 stock was added to 92 mLo f
PBS. Vehicle injections were comprised of 100% EtOH diluted in
PBS (4 mL of 100% EtOH in 96 mL of PBS for 1 mM Shield-1
injections; 8 mL of 100% EtOH in 92 mL of PBS for 2 mM Shield-
1 injections). Images of multiple XY points were acquired every 15
minutes for up to 80 hours. Image acquisition parameters were
optimized to visualize punctate zsGreen signal prior to Shield-1
administration, this resulted in clear visualization of E-cadh-zsG-
DD adherens junctions post-Shield-1 treatment but also resulted
signal saturation in later timepoints (t.12 hours).
Supporting Information
Movie S1 In vitro time-lapse video of 231LN cells
expressing tunable zsGreen in the absence and presence
of Shield-1 ligand. Top panels represent cells treated with
vehicle and the bottom panels represent cells treated with 1.0 mM
Shield-1. Images were acquired every 15 minutes in the green
(zsG-DD) and red (tdTomato) channels. Movie corresponds to
Figure 2A, B.
(MOV)
Movie S2 In vitro time-lapse video of 231LN cells with
tunable E-cadh-zsG-DD in the absence and presence of
Shield-1 ligand. Cells were treated with vehicle (top panels) and
0.2 mM Shield-1 (bottom panels) and images were acquired every
15 minutes in the green (E-cadh-zsG-DD) and red (tdTomato)
channels. Movie corresponds to Figure 5A–B.
(MOV)
Movie S3 In vivo time-lapse video of 231LN cells
expressing tunable zsG-DD in the presence and absence
of Shield-1 ligand. Images were acquired every 20 minutes in
the green (E-cadh-zsG-DD) and red (tdTomato) channels. The left
panel represents treatment with vehicle, the middle panel
in the same colony with depleted levels of 0.5 mM Shield-1; E-cadh-zsG-DD junctions gradually disperse over time and 231LN cells eventually revert to
a mesenchymal morphology. All scale bars are 25 mm. E) Quantitation of E-cadh-zsG-DD signal in 231LN-tdTomato cells in a 4-dimension image set
over the entire 28 hour time course.
doi:10.1371/journal.pone.0030177.g007
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represents treatment with 0.5 mM Shield-1 treatment. Movie
consists of maximum intensity projections for each timepoint and
corresponds to Figure 6A–C.
(MOV)
Movie S4 In vivo imaging of the prolonged effect of
stabilized E-cadh-zsG-DD protein in 231LN cells ex-
pressing tunable E-cadh-zsG-DD with 1.0 mM Shield-1
ligand treatment. 231LN micrometastatic colonies expressing
tunable zsG-DD protein were treated with Shield-1 ligand to
achieve a final in vivo concentration of 1.0 mM. An epithelial
morphology is maintained for .40 hours. Images were acquired
every 15 minutes in the green (E-cadh-zsG-DD) and red
(tdTomato) channels. Movie consists of maximum intensity
projections for each timepoint and corresponds to Figure 7A.
(MOV)
Movie S5 In vivo imaging of the treatment of 231LN
cells expressing tunable E-cadherin with 0.2 mM Shield-
1. No formation of E-cadherin-zsG based adherens junctions is
observed using a 0.2 mM concentration of Shield-1 ligand. Movie
consists of maximum intensity projections for each timepoint and
corresponds to Figure 7B.
(MOV)
Movie S6 In vivo imaging of Shield-1 mediated induc-
tion of tunable E-cadherin in 231LN cells. 231LN
micrometastatic colonies expressing tunable E-cadh-zsG-DD
protein were treated with Shield-1 ligand to achieve a final in
vivo concentration of 0.5 mM resulting in an induction effect within
24 hours of Shield-1 injection. During the induction phase, an
epithelial morphology is maintained for 12 hours. Images were
acquired every 15 minutes in the green (E-cadh-zsG-DD) and red
(tdTomato) channels. Movie consists of maximum intensity
projections for each timepoint and corresponds to Figure 7C.
(MOV)
Movie S7 In vivo imaging of Shield-1 depleted 231LN
cells expressing tunable E-cadherin. 231LN micrometastat-
ic colonies expressing tunable E-cadh-zsG-DD protein were
treated with Shield-1 ligand to achieve a final in vivo concentration
of 0.5 mM to induce an epithelial morphology over 12 hours
(Movie S6). This movie reveals events that occur during Shield-1
depletion, such as a reversion to the mesenchymal morphology
(Movie S7). Images were acquired every 15 minutes in the green
(E-cadh-zsG-DD) and red (tdTomato) channels. Movie consists of
maximum intensity projections for each timepoint and corre-
sponds to Figure 7D.
(MOV)
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